Background/Aims: The prognostic accuracy of mild cognitive impairment (MCI) in clinical settings is debated, variable across criteria, cut-offs, subtypes, and follow-up time. We aimed to estimate the prognostic accuracy of MCI and the MCI subtypes for dementia using three different cut-off levels. Methods: Memory clinic patients were followed for 2 (n = 317, age 63.7 ± 7.8) and 4-6 (n = 168, age 62.6 ± 7.4) years. We used 2.0, 1.5, and 1.0 standard deviations (SD) below the mean of normal controls (n = 120, age 64.1 ± 6.6) to categorize MCI and the MCI subtypes. Prognostic accuracy for dementia syndrome at follow-up was estimated. Results: Amnestic multi-domain MCI (aMCI-md) significantly predicted dementia under all conditions, most markedly when speed/attention, language, or executive function was impaired alongside memory. For aMCI-md, sensitivity increased and specificity decreased when the cut-off was lowered from 2.0 to 1.5 and 1.0 SD. Non-subtyped MCI had a high sensitivity and a low specificity. Conclusion: Our results suggest that aMCI-md is the only viable subtype for predicting dementia for both follow-up times. Lowering the cut-off decreases the positive predictive value and increases the negative predictive value of aMCI-md. The results are important for understanding the clinical prognostic utility of MCI, and MCI as a non-progressive disorder.

1.
Reisberg B, Ferris SH, Deleon MJ, Sinaiko E, Franssen E, Kluger A, Mir P, Borenstein J, George AE, Shulman E, Steinberg G, Cohen J: Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer type. Drug Develop Res 1988;15:101-114.
2.
Hsiung GY, Donald A, Grand J, Black SE, Bouchard RW, Gauthier SG, Loy-English I, Hogan DB, Kertesz A, Rockwood K, Feldman HH: Outcomes of cognitively impaired not demented at 2 years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias. Dement Geriatr Cogn Disord 2006;22:413-420.
3.
Nordlund A, Rolstad S, Klang O, Edman A, Hansen S, Wallin A: Two-year outcome of MCI subtypes and aetiologies in the Goteborg MCI study. J Neurol Neurosurg Psychiatry 2010;81:541-546.
4.
Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C: Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol 2009;66:1151-1157.
5.
Petersen RC: Mild cognitive impairment as a diagnostic entity. J Inter Med 2004;256:183-194.
6.
Visser PJ, Verhey FR: Mild cognitive impairment as predictor for Alzheimer's disease in clinical practice: effect of age and diagnostic criteria. Psychol Med 2008;38:113-122.
7.
Rasquin SM, Lodder J, Visser PJ, Lousberg R, Verhey FR: Predictive accuracy of MCI subtypes for Alzheimer's disease and vascular dementia in subjects with mild cognitive impairment: a 2-year follow-up study. Dement Geriatr Cogn Disord 2005;19:113-119.
8.
Arevalo-Rodriguez I, Smailagic N, Roque IFM, Ciapponi A, Sanchez-Perez E, Giannakou A, Pedraza OL, Bonfill Cosp X, Cullum S: Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2015;3:CD010783.
9.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Arlington, American Psychiatric Association, 2013.
10.
Wallin A, Nordlund A, Jonsson M, Lind K, Edman A, Gothlin M, Stalhammar J, Eckerstrom M, Kern S, Borjesson-Hanson A, Carlsson M, Olsson E, Zetterberg H, Blennow K, Svensson J, Ohrfelt A, Bjerke M, Rolstad S, Eckerstrom C: The Gothenburg MCI study: Design and distribution of Alzheimer's disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up. J Cereb Blood Flow Metab 2016;36:114-131.
11.
Reisberg B, Ferris SH, de Leon MJ, Crook T: Global Deterioration Scale (GDS). Psychopharmacol Bull 1988;24:661-663.
12.
Folstein MF, Folstein SE, McHugh PR: “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
13.
Morris JC: Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997;9(suppl 1):173-176; discussion 177-178.
14.
Wallin A, Edman A, Blennow K, Gottfries CG, Karlsson I, Regland B, Sjogren M: Stepwise Comparative Status Analysis (STEP): a tool for identification of regional brain syndromes in dementia. J Geriatr Psychiatry Neurol 1996;9:185-199.
15.
Royall DR, Mahurin RK, Gray KF: Bedside assessment of executive cognitive impairment: the executive interview. J Am Geriatr Soc 1992;40:1221-1226.
16.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, American Psychiatric Association, 2000.
17.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269.
18.
Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW: Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000;59:23-30.
19.
Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P; European Task Force on Age-Related White Matter Changes: A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318-1322.
20.
Wechsler D: Wechsler Memory Scale - Revised Manual. San Antonio, The Psychological Corporation, 1987.
21.
Wechsler D: Wechsler Adult Intelligence Scale Swedish Edition, ed 3. Sandviken, Harcourt Assessment, 1997/2003.
22.
Reitan R: The Halstead-Reitan Neuropsychological Test Battery. Tucson, Neuropsychology Press, 1985.
23.
Geffen GM, Butterworth P, Geffen LB: Test-retest reliability of a new form of the auditory verbal learning test (AVLT). Arch Clin Neuropsychol 1994;9:303-316.
24.
Meyers JK: Rey Complex Figure Test and Recognition Trial. Odessa, Psychological Assessment Resources, 1995.
25.
Binetti G, Cappa SF, Magni E, Padovani A, Bianchetti A, Trabucchi M: Visual and spatial perception in the early phase of Alzheimer's disease. Neuropsychology 1998;12:29-33.
26.
Kaplan EG, Goodglass H, Weintraub S: The Boston Naming Test, ed 2. Philadelphia, Lea & Febiger, 1983.
27.
Bandera R, Capitani E, Della Sala S, Spinnler H: Discrimination between senile dementia Alzheimer type patients and education matched normal controls by means of a 6-test set. Ital J Neurol Sci 1985;6:339-344.
28.
Stalhammar J, Ryden I, Nordlund A, Wallin A: Boston Naming Test automatic credits inflate scores of nonaphasic mild dementia patients. J Clin Exp Neuropsychol 2016;38:381-392.
29.
Spreen O, Strauss E: A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, ed 2. New York, Oxford University Press, 1998.
30.
Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A: The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 2005;76:1485-1490.
31.
Lezak MD, Lezak MD: Neuropsychological Assessment, ed 4. Oxford, Oxford University Press, 2004.
32.
Nordlund A, Rolstad S, Gothlin M, Edman A, Hansen S, Wallin A: Cognitive profiles of incipient dementia in the Goteborg MCI study. Dement Geriatr Cogn Disord 2010;30:403-410.
33.
Rolstad S, Nordlund A, Eckerstrom C, Gustavsson MH, Zetterberg H, Wallin A: Cognitive reserve in relation to abeta42 in patients converting from MCI to dementia - a follow-up report. Dement Geriatr Cogn Disord 2009;28:110-115.
34.
Jak AJ, Bondi MW, Delano-Wood L, Wierenga C, Corey-Bloom J, Salmon DP, Delis DC: Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am J Geriatr Psychiatry 2009;17:368-375.
35.
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC: Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003;326:41-44.
36.
Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, Fiorivanti M, Johnson JK, Kopke S, Schneider LS, Simmons A, Mattsson N, Zetterberg H, Bossuyt PM, Wilcock G, McShane R: Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology 2014;83:364-373.
37.
Damian M, Hausner L, Jekel K, Richter M, Froelich L, Almkvist O, Boada M, Bullock R, De Deyn PP, Frisoni GB, Hampel H, Jones RW, Kehoe P, Lenoir H, Minthon L, Olde Rikkert MG, Rodriguez G, Scheltens P, Soininen H, Spiru L, Touchon J, Tsolaki M, Vellas B, Verhey FR, Winblad B, Wahlund LO, Wilcock G, Visser PJ: Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the European prospective DESCRIPA study. Dement Geriatr Cogn Disord 2013;36:1-19.
38.
Hughes TF, Snitz BE, Ganguli M: Should mild cognitive impairment be subtyped? Curr Opin Psychiatry 2011;24:237-242.
39.
Brambati SM, Belleville S, Kergoat MJ, Chayer C, Gauthier S, Joubert S: Single- and multiple-domain amnestic mild cognitive impairment: two sides of the same coin? Dement Geriatr Cogn Disord 2009;28:541-549.
40.
Marra C, Ferraccioli M, Vita MG, Quaranta D, Gainotti G: Patterns of cognitive decline and rates of conversion to dementia in patients with degenerative and vascular forms of MCI. Curr Alzheimer Res 2011;8:24-31.
41.
Nordlund A, Gothlin M, Wallin A: Vascular disease, Alzheimer's disease biomarkers and cognition in mild cognitive impairment: additive or synergetic effects? Dement Geriatr Cogn Disord 2011;32:250-256.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.